These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24646553)

  • 1. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
    Turley RS; Tokuhisa Y; Toshimitsu H; Lidsky ME; Padussis JC; Fontanella A; Deng W; Augustine CK; Beasley GM; Davies MA; Dewhirst MW; Tyler DS
    Ann Surg; 2015 Feb; 261(2):368-77. PubMed ID: 24646553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.
    Turley RS; Fontanella AN; Padussis JC; Toshimitsu H; Tokuhisa Y; Cho EH; Hanna G; Beasley GM; Augustine CK; Dewhirst MW; Tyler DS
    Clin Cancer Res; 2012 Jun; 18(12):3328-39. PubMed ID: 22496203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.
    Beasley GM; Riboh JC; Augustine CK; Zager JS; Hochwald SN; Grobmyer SR; Peterson B; Royal R; Ross MI; Tyler DS
    J Clin Oncol; 2011 Mar; 29(9):1210-5. PubMed ID: 21343562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
    Ueno T; Ko SH; Grubbs E; Pruitt SK; Friedman HS; Tyler DS
    Am J Surg; 2004 Nov; 188(5):532-7. PubMed ID: 15546565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
    Augustine CK; Yoshimoto Y; Gupta M; Zipfel PA; Selim MA; Febbo P; Pendergast AM; Peters WP; Tyler DS
    Cancer Res; 2008 May; 68(10):3777-84. PubMed ID: 18483261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
    Beasley GM; McMahon N; Sanders G; Augustine CK; Selim MA; Peterson B; Norris R; Peters WP; Ross MI; Tyler DS
    Cancer; 2009 Oct; 115(20):4766-74. PubMed ID: 19637344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
    Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
    Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
    Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
    Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
    Yoshimoto Y; Augustine CK; Yoo JS; Zipfel PA; Selim MA; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2007 May; 6(5):1492-500. PubMed ID: 17483437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
    Toshimitsu H; Yoshimoto Y; Augustine CK; Padussis JC; Yoo JS; Angelica Selim M; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
    Ann Surg Oncol; 2010 Aug; 17(8):2247-54. PubMed ID: 20182810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
    Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
    Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
    Ueno T; Ko SH; Grubbs E; Yoshimoto Y; Augustine C; Abdel-Wahab Z; Cheng TY; Abdel-Wahab OI; Pruitt SK; Friedman HS; Tyler DS
    Mol Cancer Ther; 2006 Mar; 5(3):732-8. PubMed ID: 16546988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
    Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
    J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function.
    Khorsand M; Khajeh S; Eslami M; Nezafat N; Ghasemi Y; Razban V; Mostafavi-Pour Z
    J Cell Mol Med; 2022 Apr; 26(8):2392-2403. PubMed ID: 35224849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing melanoma treatment with resveratrol.
    Osmond GW; Augustine CK; Zipfel PA; Padussis J; Tyler DS
    J Surg Res; 2012 Jan; 172(1):109-15. PubMed ID: 20855085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
    Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
    Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.